Patents Expiring in 2026
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF MANTLE CELL LYMPHOMA | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |